5.55

3.54% 0.19

After Hours: 5.55

Prelude Therapeutics Inc (PRLD)

Overview News Price History Option Chain Financials Discussions Forecast

Prelude Therapeutics Inc stock is traded at $5.55, with a volume of 452.07K. It is up +3.54% in the last 24 hours and up +26.42% over the past month. Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

Previous Close:

$5.36

Open:

$5.45

24h Volume:

452.07K

Relative Volume:

1.07

Market Cap:

$442.91M

Revenue:

$16.72M

Net Income/Loss:

$-77.80M

P/E Ratio:

-5.2492

EPS:

-1.0573

Net Cash Flow:

$-43.78M

1W Performance:

+13.27%

1M Performance:

+26.42%

6M Performance:

+148.88%

1Y Performance:

+487.30%

1-Day Range:

$5.15

$5.61

1-Week Range:

$4.81

$5.91

52-Week Range:

$0.8221

$5.91

Prelude Therapeutics Inc Stock (PRLD) Company Profile

Name

Prelude Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(302) 467-1280

Address

175 INNOVATION BOULEVARD, WILMINGTON

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

PRLD's Discussions on Twitter

Compare PRLD vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRLD Prelude Therapeutics Inc	5.55	457.27M	16.72M	-77.80M	-43.78M	-1.0573
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-19-24	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-20-24	Downgrade	Barclays	Equal Weight → Underweight
Mar-13-24	Initiated	JMP Securities	Mkt Outperform
Feb-20-24	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-19-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Nov-21-22	Downgrade	BofA Securities	Neutral → Underperform
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jul-29-22	Initiated	Jefferies	Buy
Mar-15-22	Downgrade	BofA Securities	Buy → Neutral
Feb-28-22	Downgrade	Barclays	Overweight → Equal Weight
Oct-08-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-27-21	Upgrade	BofA Securities	Neutral → Buy
Apr-26-21	Initiated	H.C. Wainwright	Buy
Mar-09-21	Initiated	Barclays	Overweight
Nov-20-20	Downgrade	BofA Securities	Buy → Neutral
Oct-20-20	Initiated	BofA Securities	Buy
Oct-20-20	Initiated	Goldman	Neutral
Oct-20-20	Initiated	Morgan Stanley	Equal-Weight

View All

Prelude Therapeutics Inc Stock (PRLD) Latest News

Aug 13, 2026

Prelude Therapeutics Hits New 52-Week High of $5.91, Reflecting Strong Growth - MarketsMojo

Aug 13, 2026

Aug 12, 2026

Prelude Therapeutics Incorporated reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 12, 2026

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Receives Consensus Recommendation of "Hold" from Analysts - marketbeat.com

Aug 12, 2026

Prelude Therapeutics (PRLD) Stock Rallies As Losses Ease But Milestones Remain Unclear - Sahm

Aug 12, 2026

Aug 11, 2026

Prelude Therapeutics (NASDAQ:PRLD) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - marketbeat.com

Aug 11, 2026

Prelude Therapeutics Reports Q2 2026 Earnings Featuring First Revenue and Reduced Losses - Kalkine Media

Aug 11, 2026

Prelude Therapeutics Reports $13.9 Million Q2 Net Loss - Quiver Quantitative

Aug 11, 2026

Prelude Therapeutics reports Q2 2026 results: $5.7M revenue, $13.9M net loss, $155.2M cash - TradingView

Aug 11, 2026

Prelude Therapeutics reports Q2 EPS (14c), consensus (19c) - TipRanks

Aug 11, 2026

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times

Aug 11, 2026

Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows - TradingView

Aug 11, 2026

Prelude Therapeutics 2Q Loss/Shr 14c >PRLD - moomoo.com

Aug 11, 2026

Aug 06, 2026

Prelude Therapeutics (PRLD) Expected to Post Earnings on Thursday - marketbeat.com

Aug 06, 2026

Jul 31, 2026

Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High? - Yahoo Finance

Jul 31, 2026

Jul 29, 2026

Prelude Therapeutics (NASDAQ:PRLD) Earns Buy Rating from HC Wainwright - marketbeat.com

Jul 29, 2026

Jul 28, 2026

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Jul 28, 2026

EcoR1 Capital LLC Makes New $3.24 Million Investment in Prelude Therapeutics Incorporated $PRLD - marketbeat.com

Jul 28, 2026

Jul 27, 2026

PRLD|Prelude Therapeutics Inc|Price:4.640| - TradingKey

Jul 27, 2026

Jul 26, 2026